Navigation Links
Positive results from Visudyne(R) combination therapy study reported at Annual Macula Society Conference
Date:3/28/2008

VANCOUVER, March 28 /PRNewswire-FirstCall/ - QLT Inc. (NASDAQ: QLTI; TSX: QLT) announced today that results from an investigator-sponsored Phase II study, in patients with subfoveal choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD), showed that a combination therapy of verteporfin (Visudyne(R)) followed by bevacizumab (Avastin(R)) reduced, by half, the number of treatments required during the first six months to gain similar visual acuity compared to Avastin monotherapy. In addition, 30% of the patients treated using the combination therapy required only a single combination treatment compared to Avastin monotherapy, with which all patients required additional treatments.

Visudyne therapy is approved for the treatment of age-related macular degeneration (AMD) in patients with predominantly classic subfoveal choroidal neovascularization. QLT Inc. is the manufacturer of Visudyne.

Dr. Michael Potter, the investigator-sponsor of the verteporfin and bevacizumab (VIA) clinical trial, which was supported by QLT, presented results today at the 31st Annual Macula Society Meeting that is being held this week in Florida. The objective of the VIA study was to determine whether Visudyne, at low or very low fluence rates, in combination with Avastin, reduces the average number of treatments required, compared to Avastin alone.

"We are very pleased with the clinical outcomes of this study. Our goal was to see if it is possible to minimize the number of treatments while maintaining or improving visual acuity in patients with CNV secondary to AMD. At six months, virtually all the patients treated with the Visudyne combination therapy gained visual acuity with half the number of treatments required with Avastin monotherapy. These results are encouraging, and more research continues to be done to evaluate the benefits of combination therapy in terms of helping patients improve their vision and also reducing the cost of treatment," said Michael Potter, MD, FRCSC, Associate Professor, Department of Ophthalmology and Visual Sciences, Vancouver Hospital/University of British Columbia Eye Care Centre.

VIA Study Design

This study was a single centre, Phase II randomized, controlled, double-masked clinical trial involving 36 patients who were assigned to one of three treatment groups
Group 1: Low fluence Visudyne followed by Avastin

Group 2: Very low fluence Visudyne followed by Avastin

Group 3: Avastin alone

Intravitreal bevacizumab was delivered within two hours of PDT at baseline. Patients returned monthly thereafter for best-corrected ETDRS visual acuity (VA) testing, optical coherence tomography (OCT), and ocular examination. Retreatment decisions were based primarily on OCT. PDT was administered at months 0, 3, 4, 5 or 6, with a minimum 3-month interval between verteporfin/sham PDT treatments.

VIA Study Results

Thirty-five of 36 enrolled patients completed the 6-month visit. The average number of Avastin treatments in Group 3 was 5.1, compared to 2.8 in Group 1 and 2.4 in Group 2. Over 6 months, patients who were treated in the Group 1 and Group 2 required significantly fewer treatments on average than those treated in Group 3 (p=0.005 and p<0.001, respectively). Each group experienced an average improvement in visual acuity at month 6, compared to baseline (Group 1: 6.3 letters, p>0.05; Group 2: 14.1 letters, p=0.003; and Group 3: 10.8 letters, p<0.001, respectively). Both combination therapy and mono therapy used in the study were well tolerated.

Additional Study Results Reported on Visudyne Combination Therapy

Additional data demonstrating the potential benefits of Visudyne combination therapy were reported today at the Macula Society conference by: Dr. William F. Mieler, investigator and Chairman of the Registry Oversight Board Committee for QLT's two Visudyne registry studies (RVT001 and RVT002); Dr. Paolo Lanzetta, investigator for a triple therapy clinical study of ranibizumab, juxtascleral triamcinolone acetonide and Visudyne; and Dr. Albert Augustin, investigator of a triple therapy clinical study of Visudyne, dexamethasone and Avastin. Dr. Lanzetta's investigator-sponsored study was supported by Novartis AG and Dr. Albert Augustin's investigator-sponsored study was funded by QLT.

The abstracts for the studies can be found in the final conference program at: http://www.maculasociety.org/annualmeeting/final_program-08.pdf

QLT Inc. is a global biopharmaceutical company dedicated to the discovery, development and commercialization of innovative therapies. Our research and development efforts are focused on pharmaceutical products in the fields of ophthalmology and dermatology. In addition, we utilize three unique technology platforms, photodynamic therapy, Atrigel(R) and punctal plugs with drugs, to create products such as Visudyne and Eligard(R) and future product opportunities. For more information, visit our web site at http://www.qltinc.com.

Atrigel is a registered trademark of QLT USA, Inc.

Visudyne is a registered trademark of Novartis AG.

Eligard is a registered trademark of Sanofi-aventis.

QLT Inc. is listed on The NASDAQ Stock Market under the trading symbol "QLTI" and on The Toronto Stock Exchange under the trading symbol "QLT."

Certain statements contained in this press release, which are not historical facts, are "forward-looking statements," as the term is defined in the Private Securities Litigation Reform Act of 1995 and constitute "forward-looking information" within the meaning of applicable Canadian securities laws. Such forward-looking statements are predictions only and are subject to risks and uncertainties which can cause actual results to differ materially from those currently anticipated due to a number of factors, which include, but are not limited to: the completion and results of studies on combination therapy, the level of physician acceptance of Visudyne in combination with other agents and the cost associated with such treatments is uncertain, and other factors as described in detail in QLT's Annual Information Form and Annual Report on Form 10-K, quarterly reports on Form 10-Q and other filings with the U.S. Securities and Exchange Commission and Canadian securities regulatory authorities. Forward-looking statements are based on the current expectations of QLT and QLT does not assume any obligation to update such information to reflect later events or developments except as required by law.

CONTACT: QLT Inc.: Vancouver, Canada, Therese Hayes, Telephone: (604) 707-7000, or 1-800-663-5486, Fax: (604)-707-7001


'/>"/>
SOURCE QLT Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Cystic Fibrosis Foundation announces positive early results for phase 2 clinical trial of VX-770
2. MRIs high false positive rate has little impact on womens choice of preventive mastectomy
3. AcroMetrix Announces Launch of First Liquid MRSA Positive Control
4. Make Your Mammogram a Positive Experience: Author Offers Guidelines and Tips to Change Womens Negative Attitudes Toward Mammograms
5. QLT announces positive FDA action on Aczone(TM)
6. Cardiome Announces Positive Interim Phase 2b Results for Oral Vernakalant and Engages Merrill Lynch as Strategic Advisor
7. Echo Therapeutics Announces Positive Results from Symphony(TM) Transdermal Continuous Glucose Monitoring System Study at Tufts Medical Center
8. Ibuprofen destroys aspirins positive effect on stroke risk
9. Peregrine Pharmaceuticals Announces Positive Data From Cotara(R) Brain Cancer Trials
10. Positive results from phase 1 clinical trials of cuprindro
11. Single reader with CAD more efficient, yields fewer false positives, and possibly more sensitive
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... ... June 24, 2016 , ... Comfort Keepers® of San Diego, CA is excited ... To Recovery® program to drive cancer patients to and from their cancer treatments. ... highest quality of life and ongoing independence. Getting to and from medical treatments ...
(Date:6/24/2016)... ... June 24, 2016 , ... People across the U.S. are sharpening their pencils ... an essay contest in which patients and their families pay tribute to a genetic ... 2016 National Society of Genetic Counselors (NSGC) Annual Education Conference (AEC) this September. ...
(Date:6/24/2016)... ... 24, 2016 , ... The Haute Beauty Network, affiliated with ... as a prominent plastic surgeon and the network’s newest partner. , Dr. ... handsome men, look naturally attractive. Plastic surgery should be invisible.” He stands by ...
(Date:6/24/2016)... ... June 24, 2016 , ... Strategic ... Frederick area economy by obtaining investment capital for emerging technology companies. SCP ... that have already resulted in more than a million dollars of capital investment ...
(Date:6/24/2016)... ... June 24, 2016 , ... Venture Construction Group ... Tournament held on June 20th at the Woodmont Country Club at 1201 Rockville ... an organization dedicated to helping service members that have been wounded in battle and ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... June 24, 2016  Arkis BioSciences, a leading ... and more durable cerebrospinal fluid treatments, today announced ... Series-A funding is led by Innova Memphis, followed ... other private investors.  Arkis, new financing will accelerate ... the market release of its in-licensed Endexo® technology. ...
(Date:6/23/2016)... ITASCA, Ill. , June 23, 2016  In a startling ... states are failing their residents by lacking a comprehensive, proven plan ... , a definitive ranking of how states are tackling the ... rating to only four states – Kentucky , ... and Vermont . Of the 28 failing states, ...
(Date:6/23/2016)... , June 23, 2016 Bracket , a ... its next generation clinical outcomes platform, Bracket eCOA (SM) ... on June 26 – 30, 2016 in Philadelphia ... electronic Clinical Outcome Assessment product of its kind to fully ... Bracket eCOA 6.0 is a flexible platform for ...
Breaking Medicine Technology: